{'52WeekChange': 0.34661365,
 'SandP52WeekChange': 0.0644362,
 'address1': '99 Hayden Avenue',
 'address2': 'Suite 120 Building E',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 31.89,
 'askSize': 800,
 'averageDailyVolume10Day': 67362,
 'averageVolume': 91919,
 'averageVolume10days': 67362,
 'beta': None,
 'beta3Year': None,
 'bid': 25,
 'bidSize': 1100,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Lexington',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 28.15,
 'dayLow': 26.92,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -32.471,
 'enterpriseToRevenue': 77.858,
 'enterpriseValue': 583932224,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 34.206856,
 'fiftyTwoWeekHigh': 42.26,
 'fiftyTwoWeekLow': 19.1,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 8852517,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 26,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.12635,
 'heldPercentInstitutions': 0.36991,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/kerostx.com',
 'longBusinessSummary': 'Keros Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on the discovery, '
                        'development, and commercialization of novel '
                        'treatments for patients suffering from hematological '
                        'and musculoskeletal disorders with high unmet medical '
                        "need. The company's lead protein therapeutic product "
                        'candidate is KER-050, which is being developed for '
                        'the treatment of low blood cell counts, or '
                        'cytopenias, including anemia and thrombocytopenia in '
                        'patients with myelodysplastic syndromes, or MDS, and '
                        'in patients with myelofibrosis. It is also developing '
                        'small molecule product candidate KER-047 that is '
                        'being developed for the treatment of anemia, as well '
                        'as for the treatment of fibrodysplasia ossificans '
                        'progressiva, or FOP, and is currently in a Phase 1 '
                        'clinical trial; and KER-012 being developed for the '
                        'treatment of disorders associated with bone loss, '
                        'such as osteoporosis and osteogenesis imperfecta, and '
                        'for the treatment of pulmonary arterial hypertension, '
                        'or PAH. The company was founded in 2015 and is '
                        'headquartered in Lexington, Massachusetts.',
 'longName': 'Keros Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 544820864,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_333195513',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -23201000,
 'nextFiscalYearEnd': 1640908800,
 'open': 28.01,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617-314-6297',
 'previousClose': 27.87,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 72.642784,
 'profitMargins': -2.806,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 28.15,
 'regularMarketDayLow': 26.92,
 'regularMarketOpen': 28.01,
 'regularMarketPreviousClose': 27.87,
 'regularMarketPrice': 28.01,
 'regularMarketVolume': 21912,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 20148700,
 'sharesPercentSharesOut': 0.0646,
 'sharesShort': 1302544,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 625845,
 'shortName': 'Keros Therapeutics, Inc.',
 'shortPercentOfFloat': 0.18200001,
 'shortRatio': 8.56,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'KROS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 30.99212,
 'volume': 21912,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.kerostx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02421'}